Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2017

  1. Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?

    Journal of Comparative Effectiveness Research, Vol. 6, Núm. 6, pp. 491-495

2016

  1. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology

    Advances in Therapy, Vol. 33, Núm. 11, pp. 2059-2068

  2. Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas

    Archivos de Bronconeumologia, Vol. 52, Núm. 7, pp. 378-388

2015

  1. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

    Patient Preference and Adherence, Vol. 10

2014

  1. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

  1. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

    Lung Cancer, Vol. 72, Núm. 1, pp. 84-91

2007

  1. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: The Spanish Lung Cancer Group trial 9901

    Journal of Clinical Oncology, Vol. 25, Núm. 30, pp. 4736-4742

  2. XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA-B non-sinall-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery

    EJC SUPPLEMENTS

1991

  1. Lung cancer in patients under 40 years of age: a different problem?

    Medicina clínica, Vol. 97, Núm. 10, pp. 373-376